DIAN

DIAN
Name	DIAN
Formation	2008
Type	Research consortium
Headquarters	Washington, D.C.
Leader title	Director
Leader name	Reisa Sperling

DIAN

DIAN is an international research consortium focused on autosomal dominant forms of Alzheimer's disease, bringing together investigators, clinical centers, industry partners, and advocacy organizations to study early-onset familial Alzheimer disease and related biomarkers. Founded to coordinate longitudinal observational studies and interventional trials, DIAN connects clinical cohorts, geneticists, neurologists, and imaging centers to accelerate translational research and therapeutic development. The initiative integrates work across neuroimaging, molecular genetics, biomarker science, clinical neurology, and regulatory engagement to define pre-symptomatic stages and evaluate candidate treatments.

Etymology and usage

The name DIAN originates as an acronym reflecting the consortium’s mandate to study Dominantly Inherited Alzheimer disease and is widely used in the literature linking clinical trial reports, biomarker studies, and longitudinal cohort descriptions. In publications, DIAN is typically cited alongside institutions such as Harvard Medical School, Massachusetts General Hospital, Brigham and Women's Hospital, and multinational partners including University College London, McGill University, and University of California, San Francisco. The DIAN identifier appears in trial registries, consensus statements published with involvement from agencies like the Food and Drug Administration and the European Medicines Agency, and in collaborative documents with advocacy groups such as Alzheimer's Association and Alzheimer Europe.

Definitions and classifications

DIAN defines its target population as carriers of fully penetrant autosomal dominant mutations in genes classically associated with early-onset familial Alzheimer disease: APP, PSEN1, and PSEN2. Participants are classified by mutation status (mutation carriers versus non-carriers), clinical stage (asymptomatic, prodromal, symptomatic), and estimated years to symptom onset based on family-specific age at onset. The consortium applies standardized diagnostic frameworks drawing on criteria from National Institute on Aging–Alzheimer's Association workgroups and uses classifications aligned with biomarker-based frameworks developed in collaboration with expert bodies such as World Health Organization working groups and the International Working Group (IWG).

Biological and clinical significance

DIAN has elucidated the sequence of pathophysiological events in autosomal dominant Alzheimer disease, demonstrating early accumulation of amyloid beta decades before clinical decline and subsequent tau pathology and neurodegeneration. Findings link mutation-specific effects in PSEN1 and PSEN2 with altered γ-secretase activity and amyloid precursor protein processing, informing models derived from studies at institutions like Salk Institute for Biological Studies and Cold Spring Harbor Laboratory. Clinically, DIAN’s work impacts diagnostic paradigms used by neurologists at centers such as Mayo Clinic and Johns Hopkins Hospital and informs counseling practices in genetic clinics at hospitals like Cleveland Clinic and Massachusetts General Hospital. The consortium’s biomarker timeline has influenced trial design at pharmaceutical companies including Biogen, Eisai, Roche, and Lilly.

Detection and measurement methods

DIAN employs multimodal assessment combining molecular genetics, fluid biomarkers, neuroimaging, and neuropsychological testing. Genetic testing targets pathogenic variants in APP, PSEN1, and PSEN2 using methods established in clinical genetics laboratories associated with Broad Institute, Sanger Institute, and academic centers. Cerebrospinal fluid assays measure amyloid beta42/40 ratios, total tau protein and phosphorylated tau using platforms validated by research collaborations with Washington University in St. Louis and commercial partners. Neuroimaging protocols include positron emission tomography with tracers such as Pittsburgh compound B and tau ligands developed in coordination with centers like University of Pittsburgh Medical Center and Karolinska Institutet, and structural and functional magnetic resonance imaging sequences harmonized across sites including Stanford University and University of Oxford. Cognitive measures align with batteries used in trials run by organizations like Dominantly Inherited Alzheimer's Network Trials Unit and incorporate standardized neuropsychological tests employed at institutions such as University of Cambridge.

Management and interventions

DIAN supports interventional trials targeting the preclinical and symptomatic stages of autosomal dominant Alzheimer disease, evaluating anti-amyloid monoclonal antibodies, small-molecule modulators of β-secretase and γ-secretase, and anti-tau strategies. Trial infrastructure has coordinated multicenter studies with pharmaceutical sponsors including Genentech, Novartis, and academic trial networks like NIH-funded consortia. Clinical management recommendations emerging from DIAN data inform specialist care at memory clinics such as Mount Sinai Hospital and UCSF Memory and Aging Center, emphasizing genetic counseling, risk communication modeled on standards from American College of Medical Genetics and Genomics, and symptomatic treatments aligned with best practices from expert centers including Mayo Clinic.

History and research developments

DIAN was established in the late 2000s as collaborative investigators from centers including Harvard Medical School, University of California, San Francisco, and Washington University in St. Louis sought to assemble families with autosomal dominant Alzheimer disease for longitudinal study. Early milestones included demonstration of preclinical amyloid accumulation reported in high-impact venues alongside contributions from groups at Yale University, Columbia University, and University of Toronto. Subsequent phases expanded biomarker assays, standardized imaging, and launched interventional trials coordinated with regulatory agencies such as the Food and Drug Administration and research funders including National Institutes of Health and Alzheimer's Association. Ongoing research directions link DIAN cohorts to international efforts at European Commission-funded networks, genomics consortia at Wellcome Trust-supported centers, and translational pipelines at biotech firms, advancing precision medicine approaches to inherited Alzheimer disease.

Category:Neuroscience research consortia